RPRX Royalty Pharma plc
$67.27▲ +2.03%
Healthcare
Other
Volume 2.46M
Avg Volume (10D) 3.23M
Key Metrics & Fundamentals
Market Cap
$38.87B
P/E Ratio
35.8
Div Yield
1.43%
52W Range
36.03 - 67.71
% vs 50 MA
9.62%
% vs 200 MA
24.19%
RSI-14
73.8
MACD Histogram
+0.7100
Beta (1Y vs SPY)
0.23
Free Cash Flow
$728.46M
Gross Rev
$674.14M
Gross Profit
$674.14M
EBITDA
$142.12M
COGS
–
Operating Exp
$541.02M
Operating Income
$133.12M
EBIT
$133.12M
Pretax Income
$81.49M
Net Income
$17.88M
EPS (Diluted)
0.02
Price & Volume History
Loading chart…
Recent News
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears
MarketBeat · Oct 30, 2026 11:14 AM ET
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics
Zacks · Oct 30, 2026 8:15 AM ET
Should You Buy Royalty Pharma Stock Before Nov. 4?
Motley Fool · Oct 29, 2026 9:50 AM ET
Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Zacks · Oct 29, 2026 9:00 AM ET
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks · Oct 28, 2026 9:00 AM ET
Funds Load Up On Marriott, Estee Lauder As Big Tech Earnings Loom
Investor's Business Daily · Oct 28, 2026 8:00 AM ET
Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead
Motley Fool · Oct 25, 2026 10:35 AM ET
Missed Royalty Pharma's Rally? Here's The Case Holders Backed
Simply Wall St. · Oct 24, 2026 7:10 PM ET
3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell
Motley Fool · Oct 22, 2026 10:35 AM ET
Royalty Pharma declares fourth quarter 2026 dividend
GlobeNewswire · Oct 16, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See RPRX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.